However, Janelidze et al. reported no improvement in diagnostic accuracy of either prodromal AD or AD dementia when using YKL-40, compared to using core CSF AD biomarkers (Aβ and tau), although YKL-40 was selectively increased in AD and FTD patients compared to the other dementias including DLB, VAD, and Parkinson’s disease dementia (79). This evidence concerns the gene MAPT and frontotemporal dementia.